Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry

T. Harada, A. Lopez-Chavez, L. Xi, M. Raffeld, Y. Wang, G. Giaccone

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Epidermal growth factor receptor (EGFR) mutations are predictive markers for response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). The most common mutations, exon 19 short deletions and exon 20 point mutation (L858R), activate the tyrosine kinase and confer sensitivity to EGFR-TKIs. However, the function and sensitivity of rare mutations to EGFR-TKIs are unknown. In this study, we found five EGFR mutations out of 16 patients with NSCLC of African-American descent. The frequency of such mutations in this patient population appears to be significantly higher than previously reported. Two of them (N771GY and A767-V769dup) are rare insertion mutations located in exon 20. Using YFP-tagged EGFR mutants, we demonstrated that the mutations confer increased kinase activity, but no sensitivity to erlotinib at clinically available concentrations. In addition, we examined efficacy of PF00299804, an irreversible EGFR-TKI. Although the drug failed to show efficacy to T790M and S768N mutations, the exon 20 insertion mutations were sensitive to PF00299804. These data suggest that rare mutations in exon 20 are resistant to erlotinib but may be sensitive to irreversible inhibitors.

Original languageEnglish (US)
Pages (from-to)1744-1752
Number of pages9
JournalOncogene
Volume30
Issue number15
DOIs
StatePublished - Apr 14 2011

Keywords

  • African American
  • EGFR
  • EGFR-TKI
  • mutation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry'. Together they form a unique fingerprint.

  • Cite this